Blockbuster weight-loss injections, currently costing up to £200 monthly, are anticipated to see their prices plummet to as low as £20. This significant reduction is expected from early 2026, as the global patent held by Danish pharmaceutical giant Novo Nordisk for semaglutide, the active appetite-suppressing ingredient in drugs like Wegovy and Ozempic, begins to expire in numerous countries.

Semaglutide has been widely recognized as a revolutionary treatment in the battle against obesity. However, with limited availability through the NHS, hundreds of thousands of individuals in Britain have sought access via private online pharmacies, incurring substantial weekly costs for the jab. The impending patent expirations will allow rival companies to produce 'generic' versions of semaglutide, which could drive prices down by as much as 90 per cent, according to Medicines UK, an organization representing manufacturers.

Although Novo Nordisk's patent in the UK is not set to lapse until 2031, experts caution that cheaper imports are likely to enter Britain through a burgeoning 'grey market'. This unregulated supply, often sourced from international websites or social media, bypasses standard UK safety checks and carries the inherent risk of counterfeit products. Medicines UK advises against purchasing from overseas pharmacies or travelling abroad for these cut-price jabs, emphasizing that semaglutide access should always be via a prescription, with regular medical check-ins.

The arrival of generic weight-loss jabs presents a transformative opportunity for public health. Robert Russell-Pavier, director of policy and economics at Medicines UK, highlights that generic medicines typically cost 70 to 90 per cent less than their branded counterparts. This competition can compel major drug manufacturers to reduce prices, potentially even before patents fully expire. Such cost reductions would enable the NHS to treat a greater number of patients; obesity currently burdens the NHS with an estimated £6.5 billion annually, with projections indicating a rise to £9.7 billion by 2050 without effective interventions.

Generic medicines, despite potential differences in size, colour, or non-active ingredients, contain the identical active compounds as brand-name drugs and operate in the body in the same manner. They meet the same rigorous standards of quality, safety, and efficacy as all other licensed medications. Their lower cost stems from not needing to repeat the pre-clinical tests and clinical trials already conducted by the originator company, as explained by David Wallace, a senior analyst at Citeline.

The manufacturing of generic medicines adheres to strict Good Manufacturing Practice (GMP) rules. These standards are enforced in Britain by the Medicines and Healthcare products Regulatory Agency (MHRA), with similar frameworks existing under the Food and Drug Administration (FDA) in the US and the European Medicines Agency (EMA) in the EU. The World Health Organisation (WHO) also publishes GMP guidelines, ensuring consistent high quality globally.

Recently, several pharmaceutical companies have announced their intentions to apply for licences to sell generic semaglutide. Global drug firm Adalvo is preparing to offer injections across the full dosage range, while Swiss generics giant Sandoz plans to launch unbranded semaglutide next year, with discounts potentially reaching 70 per cent. Furthermore, the European Patent Office recently rejected Novo Nordisk's attempt to extend its semaglutide patent until 2033, following challenges from generic firms Teva and Galenicum Health, underscoring the sector's strong interest.

Novo Nordisk acknowledges patent expiry as a natural phase in a pharmaceutical product's lifecycle, reaffirming its commitment to ongoing innovation in new molecules and formulations for diabetes and obesity. However, in Britain, experts warn that the NHS's restricted rollout of weight-loss jabs has already fostered a 'two-tier system'. A report from the Tony Blair Institute for Global Change highlighted that higher obesity rates in deprived areas are exacerbated by the high cost of private jabs, meaning access is largely limited to the more affluent. This disparity deepens existing health divides, and online pharmacies are noted for potentially failing vulnerable groups requiring more personalized care.

Health authorities have also expressed caution regarding misuse. Doctors are reporting an increase in instances where slim women have falsely declared their weight to online chemists to obtain access. Senior medical professionals observe daily casualties in A&E units linked to appetite-suppressing injections. UK law strictly prohibits the sale of such drugs without a valid prescription. Semaglutide injections typically facilitate an average weight loss of up to 33lb (15.3kg) over 68 weeks by mimicking a natural hormone that signals fullness to the brain, thereby curbing appetite.